Premature Ejaculation – Drug Pipeline Landscape, 2022
Premature ejaculation is a type of sexual dysfunction that occurs when a man has an orgasm and ejaculates semen sooner than he or his partner would like. It often happens before or shortly after penetration during intercourse.
There are four types of ejaculation dysfunction one is premature ejaculation two delayed ejaculation three retrograde ejaculation and four Anejaculation
The most common causes of premature ejaculation include early sexual experiences and depression. Other factors include erectile dysfunction and anxiety.
Premature ejaculation patients may experience symptoms like a hormonal problem with oxytocin levels,. Abnormal hormone levels that play a role in sexual function include luteinizing hormone (LH), prolactin and thyroid stimulating hormone (TSH) and low serotonin or dopamine levels.
Healthcare provider may take a physical exam. If patient experiences early ejaculation and trouble getting or keeping an erection, healthcare provider might order blood tests to check hormone levels.
There are several treatment options for premature ejaculation depending on the cause of the disease which includes behavioral therapy, counseling and medications that includes anti-depressants, analygics and anaesthetics.
Global Insight Service’s, Premature Ejaculation – Drug Pipeline Landscape, 2022 report provides an overview of the Premature ejaculation pipeline drugs. This report covers detailed insights on Premature Ejaculation drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Premature Ejaculation pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
- Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
- Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
- Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
- Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Table of Contents
List of Tables
List of Figures
1.1 Premature Ejaculation – Pipeline Drugs, 2022-Coverage
2. Disease Overview – Premature Ejaculation
2.2 Signs and Symptoms
2.4 Disease Management
3. Premature Ejaculation – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs-Phase III
5.1.2 Fortacin spray
5.2 Clinical Stage Drugs-Phase II
5.3 Early Stage Drugs-Preclinical
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 CTC Bio, Inc
9.2 Fosun Pharma
9.3 Ixchelsis Limited
9.4 Neurohealing Pharmaceuticals Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – CDFR0812-15/CTC Bio, Inc
Table 2.2 Clinical Trial Details – IX-01/Ixchelsis Limited
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Premature Ejaculation, 2022
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Premature Ejaculation, 2022
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Premature Ejaculation, 2022
Figure 1. 4 Products by Top 5 Molecule Typeand Stage of Development for Premature Ejaculation, 2022
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Premature Ejaculation, 2022
- Assessment by Stage of Development
- Assessment by Companies
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Molecule Type
- Assessment by Route of Administration